1921
Volume 95, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Primaquine is the only licensed antimalarial drug that is capable of clearing dormant liver stage parasites. To date, there is no clear evidence of resistance of the liver stage parasite against this drug, because of the difficulty in ascertaining the cause of recurrent infection. We followed 52 Thai patients for 9 months after directly observed treatment of 15 mg primaquine daily for 14 days. Blood samples taken at 2–4 weekly intervals were assessed by microscopy and polymerase chain reaction (PCR) for the presence of parasites. Only four of 52 (7.7%) volunteers had recurrent infections, all at least 8 weeks after treatment. This demonstrates that primaquine retains a high efficacy in this population. Although a risk of new infections could not be ruled out, parasite genotyping at two polymorphic markers suggested a high probability of late relapsing infections in these volunteers. Continued monitoring of primaquine efficacy in this region is advisable.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0410
2016-11-02
2017-11-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/5/1086.html?itemId=/content/journals/10.4269/ajtmh.16-0410&mimeType=html&fmt=ahah

References

  1. Baum E, Sattabongkot J, Sirichaisinthop J, Kiattibutr K, Davies DH, Jain A, Lo E, Lee MC, Randall AZ, Molina DM, Liang X, Cui L, Felgner PL, Yan G, , 2015. Submicroscopic and asymptomatic Plasmodium falciparum and Plasmodium vivax infections are common in western Thailand—molecular and serological evidence. Malar J 14: 95.[Crossref]
  2. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RG, , 2013. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382: 900911.[Crossref]
  3. Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK, , 2014. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J 13: 488.[Crossref]
  4. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF, , 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369: 13811382.[Crossref]
  5. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, Puangsa-art S, Thanyavanich N, Maneeboonyang W, Day NP, Singhasivanon P, , 2010. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J 9: 308.[Crossref]
  6. Baird JK, Hoffman SL, , 2004. Primaquine therapy for malaria. Clin Infect Dis 39: 13361345.[Crossref]
  7. Reddy P, Flaherty JP, , 2006. Plasmodium vivax malaria relapses after primaquine prophylaxis. Emerg Infect Dis 12: 17951796.[Crossref]
  8. Orjuela-Sanchez P, da Silva NS, da Silva-Nunes M, Ferreira MU, , 2009. Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. Am J Trop Med Hyg 81: 961968.[Crossref]
  9. Bright AT, Alenazi T, Shokoples S, Tarning J, Paganotti GM, White NJ, Houston S, Winzeler EA, Yanow SK, , 2013. Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. Emerg Infect Dis 19: 802805.[Crossref]
  10. Wampfler R, Mwingira F, Javati S, Robinson L, Betuela I, Siba P, Beck HP, Mueller I, Felger I, , 2013. Strategies for detection of Plasmodium species gametocytes. PLoS One 8: e76316.[Crossref]
  11. Rosanas-Urgell A, Mueller D, Betuela I, Barnadas C, Iga J, Zimmerman PA, del Portillo HA, Siba P, Mueller I, Felger I, , 2010. Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J 9: 361.[Crossref]
  12. Restrepo E, Imwong M, Rojas W, Carmona-Fonseca J, Maestre A, , 2011. High genetic polymorphism of relapsing P. vivax isolates in northwest Colombia. Acta Trop 119: 2329.[Crossref]
  13. White NJ, Imwong M, , 2012. Relapse. Adv Parasitol 80: 113150.[Crossref]
  14. Koepfli C, Ross A, Kiniboro B, Smith TA, Zimmerman PA, Siba P, Mueller I, Felger I, , 2011. Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis 5: e1424.[Crossref]
  15. Koepfli C, Rodrigues PT, Antao T, Orjuela-Sanchez P, Van den Eede P, Gamboa D, van Hong N, Bendezu J, Erhart A, Barnadas C, Ratsimbasoa A, Menard D, Severini C, Menegon M, Nour BY, Karunaweera N, Mueller I, Ferreira MU, Felger I, , 2015. Plasmodium vivax diversity and population structure across four continents. PLoS Negl Trop Dis 9: e0003872.[Crossref]
  16. Bright AT, Manary MJ, Tewhey R, Arango EM, Wang T, Schork NJ, Yanow SK, Winzeler EA, , 2014. A high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings. PLoS Negl Trop Dis 8: e2882.[Crossref]
  17. Vanwong N, Ngamsamut N, Hongkaew Y, Nuntamool N, Puangpetch A, Chamnanphon M, Sinrachatanant A, Limsila P, Sukasem C, , 2016. Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. Drug Metab Pharmacokinet 31: 156162.[Crossref]
  18. Rijken MJ, Boel ME, Russell B, Imwong M, Leimanis ML, Phyo AP, Muehlenbachs A, Lindegardh N, McGready R, Renia L, Snounou G, Singhasivanon P, Nosten F, , 2011. Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malar J 10: 113.[Crossref]
  19. White NJ, , 2011. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 10: 297.[Crossref]
  20. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN, , 2012. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 11: 280.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0410
Loading
/content/journals/10.4269/ajtmh.16-0410
Loading

Data & Media loading...

  • Received : 20 May 2016
  • Accepted : 25 Jul 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error